The overall response rate (ORR) of pembrolizumab was 18.5% of the 27 advanced triple negative breast cancer patients with at least 1% PD-L1 expression.6 In a phase 1b JAVELIN solid tumour trial, anti-PD-L1 antibody, avelumab, showed ORR of 4.8% among 168 breast cancer patients.7 Although the ORR was low in unselected patients, ORR was 33.3% in 12 patients who had PD-L1 expressing immune cells within the tumour. Here, CD274 is linked to triple-negative breast carcinoma.